Company news

Radiopharm Theranostics Limited news in 2024

Radiopharm Theranostics Limited's news releases, calls and decks from 2024, newest first.

View company

Strategic Co-Development Partnership with Lantheus for Aus

December 29, 2024

RAD 202 receives approval to start Phase 1 therapeutic trial

December 19, 2024

Response to ASX Aware Letter

December 18, 2024

Completion of preclinical data package for RAD 402

December 9, 2024

Approval received to expand RAD204 Phase 1 trial

November 19, 2024

RAD 301 shows strong imaging potential in pancreatic cancer

November 17, 2024

RAD increases ownership in Radiopharm Ventures to 75%

August 25, 2024

FDA IND approval for Phase 2b trial in brain metastases

July 22, 2024

First patient dosed in Phase 1 therapeutic lung cancer trial

July 10, 2024

Reinstatement to Quotation

June 25, 2024

Radiopharm Theranostics completes A$70 million placement

June 25, 2024

Suspension from Quotation

June 23, 2024

Radiopharm Receives Strategic Investment for up to A$18 mill

June 20, 2024

Half Yearly Report and Accounts

February 29, 2024

Dosing begins in Phase 1 Pancreatic Imaging Study of RAD 301

February 28, 2024

Pilot Study Validates RAD Terbium-161 Radiotherapeutics

February 27, 2024

Radiopharm receives $1.9 M advance on FY24 R&D tax incentive

February 20, 2024

RAD secures Share Facility Agreement of up to A$12.5m

February 5, 2024

RAD 502 can halt tumour progression and prolong survival

February 4, 2024

Placement of Entitlement Offer Shortfall

January 23, 2024

Decks in 2024